Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seer, Inc.

2.07
-0.0600-2.82%
Post-market: 2.070.00000.00%16:39 EDT
Volume:184.31K
Turnover:382.71K
Market Cap:121.81M
PE:-1.47
High:2.11
Open:2.10
Low:2.06
Close:2.13
Loading ...

Seer announces the launch of a population-level study on biomakers

TIPRANKS
·
02 Jun

Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults

Reuters
·
01 Jun

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

GlobeNewswire
·
30 May

Seer announces launch of its new Proteograph Product Suite

TIPRANKS
·
29 May

Seer (SEER) Gets a Buy from TD Cowen

TIPRANKS
·
14 May

Seer Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Seer reports Q1 EPS (34c), consensus (36c)

TIPRANKS
·
14 May

Seer Q1 EPS $(0.34) Beats $(0.37) Estimate, Sales $4.21M Beat $3.25M Estimate

Benzinga
·
14 May

BRIEF-Seer Q1 EPS USD -0.34

Reuters
·
14 May

Seer Inc: Continues to Expect Full Year 2025 Revenue to Be in Range of $17 Million to $18 Million

THOMSON REUTERS
·
14 May

Press Release: Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Dow Jones
·
14 May

Seer Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
10 May

Castle Biosciences Reports First Quarter 2025 Results

GlobeNewswire
·
06 May

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

PR Newswire
·
02 May

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

GlobeNewswire
·
25 Apr

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

Business Wire
·
22 Apr

Metagenomi Leads The Charge With These 3 Penny Stocks

Simply Wall St.
·
09 Apr

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

GlobeNewswire
·
29 Mar

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire
·
25 Mar

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire
·
07 Mar